Superluminal Medicines Closes $120 Million Series A Round
Superluminal Medicines Closes $120 Million Series A Round to Revolutionize Drug Discovery
Boston, MA - Superluminal Medicines, Inc., a biotechnology company leveraging generative biology, chemistry, and machine learning approaches to transform the drug discovery process, announced today the closure of a $120 million Series A funding round. The investment was led by RA Capital Management, with participation from existing investors Insight Partners, NVentures (NVIDIA’s venture capital arm), and Gaingels. New investors Catalio Capital Management, Eli Lilly and Company, and Cooley LLP joined in the financing, and Diamantis Xylas, MD of Catalio, joined the Board of Directors.
The funds raised will support the progression of Superluminal’s lead program into clinical development and expand the company’s small molecule drug discovery programs focused on high-value G protein-coupled receptor (GPCR) targets. Superluminal’s platform utilizes a unique combination of human understanding, generative biology, chemistry, machine learning, and proprietary big data infrastructure to rapidly create candidate-ready compounds.
“We are grateful to have the continued support of our renowned seed investors and prominent new investors as we rapidly progress our existing high-value programs and expand our pipeline,” said Cony D’Cruz, CEO of Superluminal Medicines. “We are advancing six small molecule programs and continue to build a discovery platform to quickly and efficiently generate therapeutics for any membrane drug target.”
Andrew Levin, MD, PhD, Partner and Managing Director at RA Capital Management, expressed his continued confidence in Superluminal’s ability to revolutionize the drug discovery process. “Superluminal’s unique approach has already shown promising results in advancing difficult drug targets, and we believe their platform has tremendous potential to change the way medicines are created.”
Superluminal’s innovative approach combines generative biology, chemistry, and machine learning to create candidate-ready compounds at an unprecedented speed and accuracy. The company’s platform utilizes a proprietary big data infrastructure to rapidly generate therapeutics for any membrane drug target, making it a game-changer in the field of drug discovery.
The closing of this Series A funding round marks a significant milestone for Superluminal Medicines, and underscores the growing recognition of the company’s potential to transform the drug discovery process. With the support of prominent investors and partners, Superluminal is poised to make a lasting impact in the healthcare industry and improve the lives of millions of people around the world.
About Superluminal Medicines, Inc. Superluminal Medicines is a biotechnology company harnessing generative biology, chemistry, and machine learning approaches to revolutionize the speed and accuracy of how medicines are created. The company’s platform rapidly creates candidate-ready compounds by utilizing a unique combination of human understanding, generative biology, chemistry, machine learning, and proprietary big data infrastructure. Superluminal’s mission is to transform the drug discovery process and create life-changing medicines for high-value GPCR targets.
Contact: Superluminal Medicines, Inc. [Insert Contact Information]
